Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 56

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 56
---
 table below.

(3) The exercise price of these stock options is equal to the closing price of our common stock on the NASDAQ Global Select Market on the grant date.

(4) Amounts represent the grant date fair value of the named executive officer’s stock options and RSUs, calculated in accordance with the provisions of Accounting Standards Codification (ASC) 718, Compensation—Stock Compensation. The grant date fair value of our RSUs is based on the closing market price of the Company’s common stock on the date of grant. The grant date fair value of our stock options is calculated using a Black-Scholes valuation model. The assumptions that we used to calculate these amounts are discussed in Note 9 to our audited Consolidated Financial Statements for the year ended December 31, 2024 included in our Annual Report on Form 10-K for the year ended December 31, 2024. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.

Option Exercises and Stock Vested in Fiscal Year 2024

The following table shows certain information concerning option exercises and value realized upon the exercise of stock options and the vesting of RSU grants by our named executive officers during the fiscal year ended December 31, 2024.

| Name                      |     | Option Awards                         
 Number of shares acquired on exercise |        |     | Value       
 realized on 
 exercise(1) |           |     | Stock Awards                         
 Number of shares acquired on vesting |        |     | Value realized on vesting(2) |           |
|:--------------------------|:----|:--------------------------------------|-------:|:----|:------------|----------:|:----|:-------------------------------------|-------:|:----|:-----------------------------|----------:|
| Ryan J. Watts, Ph.D.      |     |                                       | 40,000 |     | $           | 1,080,276 |     |                                      | 75,757 |     | $                            | 1,507,781 |
| Alexander O. Schuth, M.D. |     |                                       | 92,782 |     | $           | 1,804,611 |     |                                      | 43,441 |     | $                            |   891,131 |
| Carole Ho, M.D.           |     |                                       | 17